Moderate to Severe Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Moderate to Severe Hidradenitis Suppurativa (HS) Market Outlook

Thelansis’s “Moderate to Severe Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Hidradenitis Suppurativa (HS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Hidradenitis Suppurativa (HS) Overview

Moderate to severe hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease driven by follicular occlusion and immune dysregulation, primarily affecting intertriginous areas like the axillae, groin, and perineum. Clinically, it is characterized by recurrent, deep-seated painful nodules, abscesses, draining sinus tracts, and irreversible hypertrophic scarring (typically classified as Hurley Stages II and III). Because the disease exerts a profound physical and psychological toll, management of moderate to severe HS requires aggressive, targeted systemic immunomodulation rather than simple, prolonged antibiotic courses. While TNF inhibitors historically served as the foundational biologic therapy, the standard of care has expanded to include highly efficacious IL-17 inhibitors (such as secukinumab and bimekizumab), which directly neutralize the key cytokines driving lesional inflammation. For patients with refractory structural disease, surgical excision remains critical for removing chronic tunneling, while a robust clinical pipeline of novel mechanisms—including oral JAK inhibitors and complement pathway antagonists—promises to further reshape the treatment paradigm and address significant remaining unmet needs.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Moderate to Severe Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035